Literature DB >> 24452490

Use of evidence-based pharmacotherapy for secondary prevention of coronary heart disease: a Chinese medicine hospital versus a general hospital.

Hui-min Xu1, Hong-wen Cai, Hai-bin Dai, Xiao-feng Yan, Quan Zhou, Geng Xu, Zhao-quan Huang, Wei Mao.   

Abstract

OBJECTIVE: To determine differences in adherence to secondary prevention guidelines (pharmacological interventions) among coronary heart disease (CHD) patients between a Chinese medicine (CM) hospital and a general hospital in a Chinese city.
METHODS: Medical records of 200 patients consecutively discharged from the CM hospital and the general hospital for CHD were reviewed to determine the proportions of eligible patients who received antiplatelet agents, β-blockers, angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) and statins at discharge. The effects of patient characteristics and hospital type on the use of these medicines were estimated using logistic regression models.
RESULTS: Patients discharged from the CM hospitals were older; more likely females; had greater history of hyperlipidemia, cerebrovascular diseases and less smoker (P<0.01 or P<0.05). They were less likely to receive coronary angiography and percutaneous coronary intervention, and had a longer length of stay than those discharged from the general hospital (P<0.01 or P<0.05). There were no significant differences in antiplatelet agents (96% vs. 100%, P=0.121) or statins (97.9% vs. 100%, P=0.149) use between the CM hospital and the general hospital. In multivariable analyses that adjusted for patient characteristics and hospital type, there was no significant difference in use of β-blockers between the CM hospital and the general hospital. In contrast, patients discharged from the CM hospital were less likely to receive ACE inhibitors/ARBs compared with those discharged from the general hospital (odds ratio: 0.3, 95% confidence interval: 0.105-0.854).
CONCLUSION: In this study, the CM hospital provides the same quality of care in CHD for prescribing evidence-based medications at discharge compared with another general hospital except for ACE inhibitors/ARBs use.

Entities:  

Mesh:

Year:  2014        PMID: 24452490     DOI: 10.1007/s11655-013-1663-8

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  15 in total

1.  AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation.

Authors:  Sidney C Smith; Emelia J Benjamin; Robert O Bonow; Lynne T Braun; Mark A Creager; Barry A Franklin; Raymond J Gibbons; Scott M Grundy; Loren F Hiratzka; Daniel W Jones; Donald M Lloyd-Jones; Margo Minissian; Lori Mosca; Eric D Peterson; Ralph L Sacco; John Spertus; James H Stein; Kathryn A Taubert
Journal:  Circulation       Date:  2011-11-03       Impact factor: 29.690

2.  AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute.

Authors:  Sidney C Smith; Jerilyn Allen; Steven N Blair; Robert O Bonow; Lawrence M Brass; Gregg C Fonarow; Scott M Grundy; Loren Hiratzka; Daniel Jones; Harlan M Krumholz; Lori Mosca; Richard C Pasternak; Thomas Pearson; Marc A Pfeffer; Kathryn A Taubert
Journal:  Circulation       Date:  2006-05-16       Impact factor: 29.690

3.  Health in China. Traditional Chinese medicine: one country, two systems.

Authors:  T Hesketh; W X Zhu
Journal:  BMJ       Date:  1997-07-12

4.  Attitudes to traditional Chinese medicine amongst Western trained doctors in the People's Republic of China.

Authors:  K Harmsworth; G T Lewith
Journal:  Soc Sci Med       Date:  2001-01       Impact factor: 4.634

Review 5.  Characteristics and advantages of traditional Chinese medicine in the treatment of acute myocardial infarction.

Authors:  Hong-Xu Liu; Shuo-Ren Wang; Yan Lei; Ju-Ju Shang
Journal:  J Tradit Chin Med       Date:  2011-12       Impact factor: 0.848

6.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.

Authors:  S Hulley; D Grady; T Bush; C Furberg; D Herrington; B Riggs; E Vittinghoff
Journal:  JAMA       Date:  1998-08-19       Impact factor: 56.272

7.  Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice.

Authors:  N S Vermeer; B V Bajorek
Journal:  J Clin Pharm Ther       Date:  2008-12       Impact factor: 2.512

8.  Weekend/holiday versus weekday hospital discharge and guideline adherence (from the American Heart Association's Get with the Guidelines--Coronary Artery Disease database).

Authors:  Sumit Tickoo; Gregg C Fonarow; Adrian F Hernandez; Li Liang; Christopher P Cannon
Journal:  Am J Cardiol       Date:  2008-06-28       Impact factor: 2.778

9.  Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study.

Authors:  Yufang Bi; Runlin Gao; Anushka Patel; Steve Su; Wei Gao; Dayi Hu; Dejia Huang; Lingzhi Kong; Wenhang Qi; Yangfeng Wu; Yuejin Yang; Fiona Turnbull
Journal:  Am Heart J       Date:  2008-12-17       Impact factor: 4.749

10.  Traditional Chinese medicine in the Chinese health care system.

Authors:  Judy Xu; Yue Yang
Journal:  Health Policy       Date:  2008-10-22       Impact factor: 2.980

View more
  2 in total

1.  Complex networks approach for analyzing the correlation of traditional chinese medicine syndrome evolvement and cardiovascular events in patients with stable coronary heart disease.

Authors:  Zhuye Gao; Siwei Li; Qinghua Shang; Yang Jiao; Xuezhong Zhou; Changgeng Fu; Hao Xu; Dazhuo Shi; Keji Chen
Journal:  Evid Based Complement Alternat Med       Date:  2015-03-03       Impact factor: 2.629

2.  Impacts of Clinical Pharmacist Intervention on the Secondary Prevention of Coronary Heart Disease: A Randomized Controlled Clinical Study.

Authors:  Huimin Xu; Jie Zou; Xiaoli Ye; Jiayun Han; Lan Gao; Shunbin Luo; Jingling Wang; Chunyan Huang; Xiaofeng Yan; Haibin Dai
Journal:  Front Pharmacol       Date:  2019-10-08       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.